This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

EDAP Outlines Significant Participation At 2013 American Urological Association Annual Meeting

Stocks in this article: EDAP

  • Four scientific sessions highlighting HIFU outcomes for treatment of prostate cancer
  • One AUA accepted poster presentation highlighting Sonolith lithotripter and its exclusive ultrasound Visio Track ® localization system
  • EDAP attending the FDA Public Workshop on prostate cancer clinical trial design issues

LYON, France, May 1, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced its participation at the American Urological Association (AUA) 2013 Annual Meeting, held in San Diego on May 4-8, 2013. EDAP will showcase its device portfolio at AUA booth #2845, and the Sonolith i-move will be available for live demonstrations. The Company's HIFU and lithotripsy data will be highlighted in five posters during the AUA scientific session.  

EDAP plans to attend the FDA Public Workshop entitled "Clinical Trial Design Issues – Drug and Device Development for Localized Prostate Cancer" that will be held on Sunday, May 5. The workshop will focus on trial design issues related to the development of new therapies for localized prostate cancer including patient selection, comparators, and study endpoints.

Scientific Session Highlights

Date/Time: Monday, May 6, 1:00 pm

Poster 1205: Age stratified outcomes after primary HIFU for organ localized prostate cancer in the series of 5206 patient s –  This multinational study included 5206 patients from the @-Registry (the online Ablatherm Treatment database) and found similar negative biopsy rates, higher biochemical survivals and lower morbidity for men < 70 years. HIFU had already been recognized as a therapeutic option in patients over 70 years old with 10 years life expectancy and this study demonstrates positive results in a younger population. HIFU therefore appears as a valuable therapeutic option for prostate cancer control independent of age.

Date/Time: Monday, May 6, 1:00 pm

Poster 1206 - Biochemical survival and Morbidity of High Intensity Focused Ultrasound (HIFU) as a Primary Monotherapy for Low-Risk Localized Prostate Cancer: Outcomes from the @-Registry following the ENLIGHT Trial inclusion criteria

The objective of this study was to report the biochemical and biopsy outcomes along with the morbidity of a population of low risk localized prostate cancer patients who meet the the FDA trial inclusion criteria. With a follow-up extending to 18 years, only 8.7% of patients received salvage treatment after HIFU. HIFU achieved good biochemical control at 10 years of follow-up for low risk cancer patients and negative biopsy rates were high. Ablatherm® HIFU treatment appears as a valuable and safe therapy for long term low risk prostate cancer treatment.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs